Novo Nordisk announced steep list‑price reductions for its GLP‑1 medicines, lowering monthly list prices to $675 effective 2027 as the company responds to pricing pressure and competitive data wins by rivals. The move follows recent clinical setbacks and market share shifts. Novo also publicized encouraging Phase II results from a partnered triple‑agonist program, but executives framed the pricing change as part of broader repositioning to address affordability and payer access. The price actions are likely to reverberate across the obesity/diabetes market, impacting payer negotiations, direct‑to‑consumer offerings, and rival pricing strategies.